Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yukie Yoshii"'
Autor:
Kimiteru Ito, Makoto Ueno, Kenichiro Naito, Taiga Yamaya, Hideaki Tashima, Tomoko Tachibana, Hiroaki Kurihara, Tadashi Watabe, Kazuhiro Ooe, Sei Yoshida, Jun Hatazawa, Fukiko Hihara, Eku Shimosegawa, Ming-Rong Zhang, Tatsuya Higashi, Yukie Yoshii, Atsuo Waki, Hiroki Matsumoto, Chika Igarashi
Publikováno v:
Pharmaceuticals
Volume 14
Issue 10
Pharmaceuticals, Vol 14, Iss 950, p 950 (2021)
Volume 14
Issue 10
Pharmaceuticals, Vol 14, Iss 950, p 950 (2021)
Objectives: To improve the prognosis of pancreatic cancer, new imaging methods to identify tumor lesions at a size of <
1 cm are urgently needed. To approach this clinical issue, we developed a new method to detect small tumor lesions in the p
1 cm are urgently needed. To approach this clinical issue, we developed a new method to detect small tumor lesions in the p
Autor:
Hiroki Matsumoto, Takako Furukawa, Tatsuya Higashi, Atsushi B. Tsuji, Yukie Yoshii, Tsuneo Saga, Mitsuyoshi Yoshimoto, Yasuhisa Fujibayashi, Masayuki Inubushi, Ming-Rong Zhang
Publikováno v:
Oncotarget
// Yukie Yoshii 1 , Mitsuyoshi Yoshimoto 2 , Hiroki Matsumoto 3 , Takako Furukawa 1, 4 , Ming-Rong Zhang 1 , Masayuki Inubushi 5 , Atsushi B. Tsuji 1 , Yasuhisa Fujibayashi 1 , Tatsuya Higashi 1 and Tsuneo Saga 1, 6 1 National Institute of Radiologic
Autor:
Hironori Aoyama, Hidekatsu Wakizaka, Takako Furukawa, Yasuhisa Fujibayashi, Tsuneo Saga, Ming-Rong Zhang, Naoya Adachi, Yukie Yoshii
Publikováno v:
International Journal of Oncology. 48:1477-1484
Colon cancer is one of the leading causes of cancer death worldwide. Adjuvant chemotherapy following primary surgical treatment is suggested to be beneficial in eradicating invisible disseminated small tumors in colon cancer; however, an effective dr
Autor:
Hiroko Endo, Yukie Yoshii, Zhao Hui Jin, Masahiro Inoue, Sumitaka Hasegawa, Qinghua Yuan, Yasuhisa Fujibayashi, Tsuneo Saga, Ming-Rong Zhang, Winn Aung, Takako Furukawa
Publikováno v:
Nuclear Medicine and Biology. 41:653-659
Introduction The intratumoral distributions of [ 18 F]FDG and [ 64 Cu]Cu-ATSM have been reported to be similar in adenocarcinomas but different in squamous cell carcinoma (SCC) in clinical studies. In the present study, we compared the intratumoral d
Autor:
Ryo Watanabe, Hidehiko Okazawa, Yukie Yoshii, Hiroshi Yoshii, Yasushi Kiyono, Tatsuya Asai, Takako Furukawa, Tetsuya Mori, Yasuhisa Fujibayashi, Michael J. Welch
Publikováno v:
Nuclear Medicine and Biology. 38(2):151-157
Introduction 64 Cu-diacetyl-bis ( N 4 -methylthiosemicarbazone) ( 64 Cu-ATSM) is an imaging agent for positron emission tomography (PET) that targets hypoxic tumors. 64 Cu-ATSM is also reported to be a potential agent for internal radiotherapy. In a
Autor:
Yasushi Kiyono, Myungmi Oh, Ryo Watanabe, Atsuo Waki, Hiroshi Yoshii, Hidehiko Okazawa, Tetsuya Mori, Michael J. Welch, Yukie Yoshii, Yasuhisa Fujibayashi, Takako Furukawa, Tatsuya Asai
Publikováno v:
Nuclear Medicine and Biology. 37:395-404
Introduction 64 Cu-diacetyl-bis ( N 4 -methylthiosemicarbazone) ( 64 Cu-ATSM) is a potential imaging agent of hypoxic tumor for use with PET. Recent literature demonstrated that cancer cells expressing CD133, which is a frequently used marker for so-
Autor:
Tsuneo Saga, Ming-Rong Zhang, Hiroko Endo, Yasuhisa Fujibayashi, Masahiro Inoue, Yukie Yoshii, Takako Furukawa, Qinghua Yuan, Winn Aung, Zhao Hui Jin, Sumitaka Hasegawa
Publikováno v:
Oncology reports. 34(3)
Positron emission tomography (PET) imaging of tumor hypoxia provides valuable information for cancer treatment planning. Two types of PET tracers, nitroimidazole compounds and [62,64Cu] copper-diacetyl-bis[N(4)-methylthio- semicarbazone] (Cu-ATSM), h
Autor:
Yukie Morokoshi, Yasuhisa Fujibayashi, Hiroshi Yoshii, Takako Furukawa, Hidekatsu Wakizaka, Mitsuyoshi Yoshimoto, Hiroki Matsumoto, Chizuru Sogawa, Tsuneo Saga, Ming-Rong Zhang, Yukie Yoshii
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 1, p e86996 (2014)
PLoS ONE, Vol 9, Iss 1, p e86996 (2014)
Purpose (64)Cu-diacetyl-bis (N (4)-methylthiosemicarbazone) ((64)Cu-ATSM) is a promising theranostic agent that targets hypoxic regions in tumors related to malignant characteristics. Its diagnostic usefulness has been recognized in clinical studies.